OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
JAMA Oncology	782
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	469
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	377
Error in Text	318
Errors in Key Points and Abstract	310
Stargazers	299
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	285
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	278
Overall Survival in the CAIRO5 Clinical Trial	264
Piercing the Fog	243
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	234
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	209
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	203
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	202
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	191
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	191
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	188
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	175
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	161
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	157
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	157
Her Defiance	154
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	150
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	149
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	144

Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors	144
The Multidisciplinary Cancer Conference	141
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	139
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	139
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	136
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	135
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer	134
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	128
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	126
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	124
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	116
The SOUND Randomized Clinical Trial Results	115
Results of the TARGET-TP Randomized Clinical Trial	113
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	109
An Atypical Rash on the Chest	103
Immunotherapy Before Chemoradiotherapy—More Is Better?	101
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	100
Clinical Trial Diversity—Will We Know It When We See It?	97
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	97
Shifting Toward Precision Oncology in SCLC Treatment	96
Trauma	96
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	95
JAMA Oncology	95
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	92
Coding Errors in Study of Eligibility for Lung Cancer Screening	92
Challenges in Interpreting MELATORCH Trial Outcomes—Reply	91
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	90
Error in Text	89
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	86
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	86
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	86
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	86
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	84
JAMA Oncology	84
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	83
Rethinking End Points in Modern Oncology Trials—Beyond the P Value	83
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer	82
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	82
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	82
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	82
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis	81
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	80
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	80
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	80
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	79
Variability in COVID-19 Vaccine Response Among People With Cancer	78
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	78
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	76
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	76
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	75

Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	75
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	74
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	73
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	73
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	71
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	70
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	69
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	69
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	69
Change of Article Status to Open Access	69
JAMA Oncology	69
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	69
Challenges in Shared Care Research in Hematopoietic Cell Transplantation—Reply	68
The ORATOR Trials Have Spoken—Where Do We Go From Here?	68
JAMA Oncology	68
Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma	67
Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	66
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	65
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	65
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	65
Lullaby for a Dying Self	63
Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality	63
Enlightening a Path Forward for Patients With Advanced Acral Melanoma	63
Physical Activity, Lifestyle, and Cancer Risk	61
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	61
Young-Onset Colorectal Cancer Mortality by Education	61
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score	60
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	60
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	60
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	59
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	59
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	59
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	59
Characterizing Lung Cancer in Li-Fraumeni Syndrome	58
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	58
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	57
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	57
Global Stage Distribution of Breast Cancer at Diagnosis	57
Endocrine Society Hypercalcemia of Malignancy Guidelines	57
Sunsets	56
JAMA Oncology	55
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	55
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	54
JAMA Oncology	54
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	53
Valid Analysis of Brain-Specific Progression-Free Survival	53
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ	53
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	53
Errors in Figures 2 and 3	52
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	52
Relentless	52
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	51
Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments	51
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	51
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	51
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	51
Artificial Intelligence—From Starting Pilots to Scalable Privilege	50
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	50
Error in Denominator in Results Text	50
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	50
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	49
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	49
Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity?—Reply	48
Reshuffle	48
Cancer Research and Public Health Literacy—Making Sense	48
The Time for Cancer Vaccines Is Now	48
The Vocabulary of Survival	47
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	47
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	47
Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects	47
Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems	47
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	46
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	46
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	46
Management of Down Syndrome–Associated Leukemias	46
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	46
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	46
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	45
JAMA Oncology	45
Scattered Painful Papulonodules in an Older Woman	45

Public Awareness of the Association Between Alcohol and Cancer in the US	45
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	45
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	45
The SOUND Randomized Clinical Trial Results—Reply	44
Two Hands, One Journey	44
Change of Article Status to Open Access	44
Dog Aloisanov Helped Diagnose My Cancer	44
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	43
Errors in Figure 3	43
Error in Figure 1	43
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	42
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	41
Somebody Else’s Palms	41
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	41
Financial Toxicity Among Asian American Cancer Survivors	40
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	40
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate—A Good-Risk Shift	40
Error in Figure 1	40
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply	40
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	40
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	39
Unintended Consequences of Patient Portal Access	39
PARP Inhibitors for Breast Cancer Treatment	38
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	38
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	38
Error in Figure	38
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	38
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	38
Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males	38
Risk Factors for Valvulopathy Among Childhood Cancer Survivors	37
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	37
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	36
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	36
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	36
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	36
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	36
Change to Open Access Status	35
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	35
Change to Open Access	35
Error in the Additional Contributions Section	35
A Case of Multiple Hemorrhagic Friable Nodules	35
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	35
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	35
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	35
Government Funding for the Development of Enzalutamide	35
Childhood Cancer Survivor Risk Estimates and Age, Overdispersion, and Social Context—Reply	35
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2	34
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	34
Overall Survival in the CAIRO5 Clinical Trial	34
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials	34
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	34
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?	34
Blood Clots, or Thrombosis, in Patients With Cancer	34
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	34
High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases	33
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	33
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	33
JAMA Oncology	32
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer	32
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer	32
Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer	32
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	32
A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening	32
Survival Without Adjuvant Therapy for Low-Risk Endometrial Cancer With Isolated Tumor Cells	31
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	31
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer	31
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens	31
Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis	31
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	31
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	31
Nontumor Cells in Tumor Samples Bias Expression-Based Models	30
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma	30
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?	30
FOLFOX/FOLFIRI–Bevacizumab for Unresectable Colorectal Liver Metastases	29
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis—Reply	29
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship	29
JAMA Oncology—The Year in Review, 2023	29
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply	29
A Partnership to Advance Care of Patients With Acute Promyelocytic Leukemia	29
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer	29
Postoperative Management of Prostate Cancer—Optimizing Prostate Cancer Care	29
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance	29
Keeping the Heartbeat Off-Target in Cancer Therapy	29
Results of the TARGET-TP Randomized Clinical Trial—Reply	29
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer	28
Muscle Mass, Fragility, Weight Loss, and Cancer Treatment	28
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer	28
Misinterpretation of Surgeons’ Statements on Cancer Removal—The Adverse Effects of “We Got It All”	28
Prone Whole-Breast Radiotherapy—Better Than Supine?	28
FDG PET Scans in Cancer Care	28
Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum	28
Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants	28
Errors in Table	28
Watch and Wait for Near-Complete Responders—A Word of Caution	28
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma	28